We summarise general features of HS and discuss particular characteristics of this disorder
in adults. Furthermore, we describe a simple screening and diagnostic algorithm based on …

Background In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP),
showed a high level of activity in patients who had metastatic, castration-resistant …

Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) …

Several hypotheses have been proposed to explain how antiangiogenic drugs enhance the
treatment efficacy of cytotoxic chemotherapy, including impairing the ability of chemotherapy-…

Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

We have been studying the molecular and cellular basis of chronic low-dose, frequently
administered, metronomic chemotherapy regimens for the treatment of cancer in a variety of …

Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy
thought to have an antiangiogenic basis. However, the advantages of reduced toxicity, …

The underlying mechanisms of reactive macrophage activation syndromes (rMAS) are not
understood in detail, and there is no specific treatment. This observational study was …

The survival benefits of traditional maximum tolerated dose (MTD) cytotoxic therapy have
been modest for the treatment of most types of metastatic malignancy and, moreover, often …

Radiation resistance poses a major clinical challenge in cancer treatment, but little is known
about how microRNA (miR) may regulate this phenomenon. In this study, we used next-…